Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

• Proceeds to support Phase…

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Ghent, Belgium – August 29,…

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

• Collaboration to make use…

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Collaboration to make use of…

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo to receive upfront and…

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Confo Therapeutics Doses First Subjects…

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics Enters Collaborative Agreement…

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory…

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of…